Holen Sie sich die Stockscreener-App
0.5229
3.26%
0.0165
Handel nachbörslich:
.53
0.0071
+1.36%
Schlusskurs vom Vortag:
$0.5064
Offen:
$0.4978
24-Stunden-Volumen:
1.26M
Relative Volume:
0.52
Marktkapitalisierung:
$48.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.23M
KGV:
-1.2232
EPS:
-0.4275
Netto-Cashflow:
$-34.82M
1W Leistung:
+8.04%
1M Leistung:
-16.05%
6M Leistung:
-77.27%
1J Leistung:
-28.98%
1-Tages-Spanne:
$0.49
$0.535
1-Wochen-Bereich:
$0.432
$0.535
52-Wochen-Spanne:
$0.432
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Firmenname
Context Therapeutics Inc
Sektor
Branche
Telefon
267-225-7416
Adresse
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.5229 | 43.17M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-11-25 | Eingeleitet | D. Boral Capital | Buy |
| 2024-05-16 | Eingeleitet | Piper Sandler | Overweight |
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
MPM BioImpact reports 1.4% stake in Context Therapeutics (CNTX) common stock - Stock Titan
Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan
Context Therapeutics Narrows Pipeline as Quarterly Loss Widens - MyChesCo
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - moomoo.com
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – FWB:6K9 - TradingView
LifeSci Capital downgrades Context Therapeutics (CNTX) to a Hold - The Globe and Mail
Context Therapeutics Inc (CNTX) Stock News Today - TradingKey
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context Therapeutics Inc. Stock 12‑Month Price Target Cut to $4.56, Implies 557% Upside - TradingView
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Benzinga
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results, Misses Expectations By $0.05 EPS - marketbeat.com
Context Therapeutics Highlights Progress in T Cell Engager Pipeline - TipRanks
Context Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Context Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - The Manila Times
Context Therapeutics Ends CT-95, Focuses on Two Cancer Programs - Stock Titan
Context Therapeutics Inc. 1H 2026: Net income $(23.24)M, Diluted EPS $(0.24) — 10-Q Summary - TradingView
Context Therapeutics (NASDAQ: CNTX) reports $23.2 million loss and cash runway - Stock Titan
CNTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
CNTX: CTIM-76 and CT-202 prioritized; $43M cash funds operations into Q4 2027; net loss rises - TradingView
Weekly Recap: CNTX Nasdaq notice and Q2 2026 $0.09 loss forecast - TradingView
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice - The Globe and Mail
Context Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Context Therapeutics (CNTX): Octagon group reports 3.3% beneficial stake in Schedule 13G/A - Stock Titan
Context Therapeutics (CNTX) Projected to Release Quarterly Earnings on Wednesday - marketbeat.com
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – FWB:6K9 - TradingView
CNTX|Context Therapeutics Inc|Price:0.603|Chg%:+0.003 - TradingKey
BlackRock (NYSE: BLK) discloses 6.7% ownership of Context Therapeutics (CNTX) - Stock Titan
Octagon Capital Advisors LP Takes $13.76 Million Position in Context Therapeutics Inc. $CNTX - marketbeat.com
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Context Therapeutics Inc (CNTX) Balance Sheet - TradingKey
Context Therapeutics Inc (CNTX) Income Statement - TradingKey
Context Therapeutics Inc (CNTX) Cash Flow - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – DUS:6K9 - TradingView
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Earnings Date & Reports & Earnings News - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics, Inc. Revenue Breakdown – SWB:6K9 - TradingView
Context Therapeutics Inc. Revenue Breakdown – BOATS:CNTX - TradingView
Context Therapeutics Inc. (CNTX) Slips 2.7% as Shares Approach Key SupportGamma Squeeze - po-news-eg.net
Context Therapeutics (NASDAQ:CNTX) Lowered to Strong Sell Rating by Wall Street Zen - marketbeat.com
CNTX Q1 2026 Earnings: Beat on EPS as Clinical Pipeline AdvancesEarnings Manipulation Risk - dars.gov.et
SRNE stock holds on Sorrento Therapeutics identity and filing context - ad-hoc-news.de
Context Therapeutics Inc. (CNTX) Q1 2026 Earnings: Narrowing Loss Beats Street Estimates, Stock Holds Steady - dars.gov.et
Enterprise value to revenue forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Context Grants 146,000-Share Option to New Employee - MyChesCo
Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):